Llwytho...
Current state of immunotherapy for non-small cell lung cancer
Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epid...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Transl Lung Cancer Res |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AME Publishing Company
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420529/ https://ncbi.nlm.nih.gov/pubmed/28529902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2017.03.01 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|